Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

Launched by MCMASTER UNIVERSITY · Oct 28, 2021

Keywords

ClinConnect Summary

The SNACS trial is studying whether a lower dose of a medication called Celestone, given to pregnant people at risk of preterm birth, is as effective as the standard higher dose. Celestone is a type of antenatal corticosteroid that helps improve the development of a baby's lungs, which can reduce the chances of serious health problems in preterm infants. In this trial, researchers are looking at whether giving 12 mg (instead of the usual 24 mg) can still provide the same benefits.

To participate in this trial, pregnant individuals between the ages of 18 and 55 who are at risk of delivering their baby early and have received only one dose of Celestone within the last 24 hours may be eligible. Participants will need to provide informed consent before joining the study. This trial is currently recruiting, and it’s important to know that certain health conditions or previous participation in the trial may disqualify someone from taking part. If you or someone you know fits the criteria and is interested, this study could contribute to improving care for preterm births.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or twins between 22 weeks and 0 days and \<34 weeks and 6 days gestation who have received only a single dose of Celestone within 24 hours
• • 2. Capable of giving informed, written consent.
• Exclusion Criteria:
• • 1. Contraindication to corticosteroids
• • 2. Systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus, severe asthma, Covid, etc).
• • 3. Previous participation in this trial (in a previous pregnancy)
• • 4. Known severe/life-threatening fetal or pregnant patient condition (e.g. fetal congenital/chromosomal abnormality)
• • 5. Demise of one or more fetuses after 14 weeks and 0 days